Zhongshan Lienpu Pharmaceutical

Zhongshan Lienpu Pharmaceutical is a China-based biotechnology company specializing in the research, development, and manufacturing of innovative peptide and small molecule therapeutics. The company focuses on metabolic diseases, endocrine disorders, and cardiovascular health, with a particular emphasis on multi-target agonists for obesity and type 2 diabetes. Its lead candidate, LP-101, is a dual GLP-1 and GIP receptor agonist currently in Phase 2 clinical development. Lienpu operates a state-of-the-art GMP manufacturing facility in Zhongshan to support its internal pipeline and potential CDMO services. The company is led by a team of industry veterans with extensive experience in peptide chemistry and drug delivery.